Solventum (SOLV) Valuation Check After Recent Share Price Softness

Simply Wall St

Sun, February 15, 2026 at 4:09 PM GMT+9 3 min read

In this article:

SOLV

-0.53%

Find your next quality investment with Simply Wall St’s easy and powerful screener, trusted by over 7 million individual investors worldwide.

Solventum: Stock Snapshot Following Recent Moves

Solventum (SOLV) has been drawing attention after recent trading left the shares around $75.55, with mixed shorter term returns and modest revenue and net income growth over the past year.

See our latest analysis for Solventum.

Over the past month, Solventum’s share price return of a 4.9% decline and a year-to-date share price return of a 4.4% decline contrast with a 1-year total shareholder return of 1.8%. This suggests that recent momentum has softened even as longer-term holders have seen modest gains.

If this price action has you looking beyond a single healthcare name, it could be a moment to broaden the search and check out 25 healthcare AI stocks as a starting list of ideas.

With the shares around $75.55, modest revenue and net income growth, and a value score of 5, the key question is whether Solventum is quietly undervalued at this level or if the market is already pricing in future growth.

Most Popular Narrative: 15.4% Undervalued

With Solventum last closing at $75.55 against a widely followed fair value estimate of $89.25, the current price sits below what this narrative implies.

The company’s new product innovation pipeline (notably in Negative Pressure Wound Therapy, advanced wound care, sterilization, and digital health solutions such as autonomous coding) is gaining traction, positioning Solventum to benefit from rising global demand for technologically advanced healthcare equipment, ultimately supporting future topline and earnings growth.

Read the complete narrative.

Want to see what kind of revenue profile and margin lift would need to line up with that story? The fair value hinges on a tight mix of growth, profitability and the 8.47% discount rate that anchors the whole model. The full narrative lays out how those moving parts connect, and what has to go right for $89.25 to make sense.

Result: Fair Value of $89.25 (UNDERVALUED)

Have a read of the narrative in full and understand what’s behind the forecasts.

However, there are still watchpoints, including separation and ERP execution issues or softer demand after early order timing benefits that could challenge this underpriced story.

Find out about the key risks to this Solventum narrative.

Build Your Own Solventum Narrative

If you look at this and feel your own view is different, or you simply want to test the numbers yourself, you can build a custom thesis in just a few minutes, starting with Do it your way.

Story continues  

A great starting point for your Solventum research is our analysis highlighting 3 key rewards and 2 important warning signs that could impact your investment decision.

Looking for more investment ideas?

If Solventum has sharpened your interest, do not stop here. The wider market holds plenty of other opportunities worth putting on your radar right now.

Target stability with companies that prioritize strong finances by scanning our solid balance sheet and fundamentals stocks screener (45 results) as a foundation for your next watchlist additions.

Zero in on potential mispricings by reviewing our 53 high quality undervalued stocks that filters for quality names trading at what appears to be a discount.

Spot future standouts early by running through our screener containing 23 high quality undiscovered gems before these stories attract broader attention.

_ This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned._

Companies discussed in this article include SOLV.

Have feedback on this article? Concerned about the content? Get in touch with us directly._ Alternatively, email editorial-team@simplywallst.com_

Terms and Privacy Policy

Privacy Dashboard

More Info